Group 1 - Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd. has been established with a registered capital of 10 million yuan [1] - The company's business scope includes elderly care services, remote health management services, medical research and experimental development, as well as engineering and technology research and experimental development [1] - The company is wholly owned by Xintian Pharmaceutical (002873) [1]

Group 1 - The company, New Tian Pharmaceutical, reported that as of August 29, 2025, the number of shareholders is 35,781 [2]

Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd. has established a wholly-owned subsidiary, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd., with an investment of 10 million RMB to enhance its health food production and sales capabilities [2] Company Overview - Guizhou Xintian Pharmaceutical was founded on August 11, 1995, with a registered capital of 2,441.03806 million RMB [2] - The company specializes in the research, production, and sales of traditional Chinese medicine [2] - The current chairman is Dong Dalun, and the company employs 1,682 people [2] Business Strategy - The new subsidiary will focus on health food production, food sales, and health consulting services [2] - The investment aligns with the company's strategic development plan and aims to diversify its product matrix and improve operational scale and profitability [2] Financial Performance - Projected revenues for 2024 and Q2 2025 are 858 million RMB, 193 million RMB, and 358 million RMB, with year-on-year changes of -10.11%, 8.93%, and -18.88% respectively [3] - The net profit attributable to the parent company for the same periods is projected to be 52.3229 million RMB, 4.1875 million RMB, and 5.7661 million RMB, with year-on-year declines of -35.30%, -73.11%, and -80.99% respectively [3] - The company's asset-liability ratios for the same periods are 38.75%, 37.48%, and 37.03% [3] Risk Factors - The company has 31 internal risk alerts and 38,039 external risk alerts, indicating a significant level of risk exposure [3]

Group 1 - The company announced that its wholly-owned subsidiary, Shanghai Shuo Fang Pharmaceutical Technology Co., Ltd., received a patent for a method to detect the fingerprint spectrum of ginkgo biloba decoction [1] - The acquisition of this patent is expected to enhance the company's intellectual property protection system and strengthen its core competitiveness through continuous innovation [1] - The company specializes in the research, development, production, and sales of traditional Chinese medicine, focusing on gynecological and urological medications, among other areas [1][2] Group 2 - The company adheres to a philosophy of combining traditional formulas with modern technology to improve clinical efficacy, ensuring a comprehensive approach to drug development [2] - The company’s product lineup includes unique varieties that cover multiple therapeutic areas, with a strong emphasis on clinical efficacy and inclusion in national basic drug and medical insurance directories [3] - The leading products, such as Kuntai capsules and Ningpitai capsules, are recognized as unique patented varieties with significant market barriers and pricing advantages [3] Group 3 - In the first half of 2025, the company achieved a revenue of 358 million yuan and a net profit of 5.77 million yuan attributable to shareholders [4]

Core Points - The company, New Tian Pharmaceutical, announced that its wholly-owned subsidiary, Shanghai Shuo Fang Pharmaceutical Technology Co., Ltd., has received a patent certificate from the National Intellectual Property Administration for an invention titled "A Method for Detecting the Fingerprint Spectrum of Ginkgo Biloba Decoction and Its Fingerprint Spectrum" [2] Summary by Category - **Company Announcement** - New Tian Pharmaceutical has successfully obtained a patent for a new method related to Ginkgo Biloba [2] - **Intellectual Property** - The patent is aimed at enhancing the detection and analysis of Ginkgo Biloba decoction, which may provide a competitive edge in the pharmaceutical industry [2]

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Group 1 - The company has established a wholly-owned subsidiary, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd., with an investment of 10 million RMB to enhance its pharmaceutical industry layout and accelerate the research and development of health food [1][2] - The subsidiary is registered with a capital of 10 million RMB and will focus on various health food production and sales, including special medical purpose formula foods and infant formula foods [1][2] - This investment aligns with the company's strategic development plan to improve its diversified product matrix and aims to enhance overall profitability and risk resistance [1][2] Group 2 - The establishment of the subsidiary is not expected to harm the interests of the company or its shareholders and will not negatively impact the company's operations [2] - The company plans to conduct its business activities prudently and in compliance with regulations, aiming for favorable investment returns while being aware of potential market and policy risks [2]

证券代码：002873 证券简称：新天药业 公告编号：2025-053 根据《深圳证券交易所股票上市规则》、《公司章程》等相关规定，本次对 外投资金额未达到董事会或股东会的审议标准，无需提交董事会和股东会审议。 本次投资事项不涉及关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 | 名称 | 贵州中道中医药健康科技有限公司 | | --- | --- | | 统一社会信用代码 | 91520112MAEURRW39J | | 类型 | 有限责任公司（非自然人投资或控股的法人独资） | | 住所 | 贵州省贵阳市乌当区新创路街道新添大道 号 114 | | 法定代表人 | 魏茂陈 | 二、设立全资子公司的基本情况 贵阳新天药业股份有限公司 关于对外投资设立全资子公司并完成 工商注册登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资情况概述 贵阳新天药业股份有限公司（以下简称"公司"）为进一步加大综合性医药 产业布局，加快实现保健食品研发与成果转化，完善公司多元化产品矩阵，促进 市场销售规模提升，公司以自有资金人民币 ...

Core Viewpoint - The company has established a wholly-owned subsidiary, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd., with an investment of 10 million RMB to enhance its product matrix and overall profitability [1] Group 1: Investment Details - The investment amount is 10 million RMB, aimed at promoting the research and development of health food and its transformation into products [1] - The registered capital of Zhongdao Health is exactly 10 million RMB, with Wei Maochen as the legal representative [1] - The establishment date of the subsidiary is September 1, 2025, and it has received a business license from the Market Supervision Administration of Wudang District, Guiyang City [1] Group 2: Business Scope - The business scope of the new subsidiary includes the production of health food, special medical purpose formula food, infant formula food, food additives, dairy products, beverages, and food sales [1] - This diversification aims to enhance the company's overall profitability and risk resistance [1] - The investment aligns with the company's strategic goal of becoming a comprehensive pharmaceutical enterprise [1]

Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd. has received a patent for a method to detect the fingerprint spectrum of ginkgo biloba decoction, which enhances its intellectual property protection and strengthens its core competitiveness through technological innovation [1][2]. Summary by Sections Patent Details - The patent is titled "A Method for Detecting the Fingerprint Spectrum of Ginkgo Biloba Decoction" with certificate number 8210031 [1]. - The patent was granted to Shanghai Shuo Fang Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company [1]. - The patent application was filed on June 19, 2023, and the authorization announcement date is August 29, 2025 [1]. Technological Significance - The patented technology allows for comprehensive detection of the types and quantities of chemical components in ginkgo biloba, establishing a fingerprint spectrum method [1]. - This method will provide a basis for the use of high-quality medicinal materials in product production, ensuring product quality [1]. Impact on Company Operations - The acquisition of this patent is not expected to have a significant impact on the company's production and operations but will enhance the company's intellectual property protection system [2]. - The technology is anticipated to be utilized in the production of new drug products, improving the stability and effectiveness of the company's offerings [1][2].